Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 2013, 122: 1293-1304. PMID: 23836560, PMCID: PMC3744994, DOI: 10.1182/blood-2013-05-501072.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisAptamers, PeptideBiomarkers, TumorBlotting, WesternBRCA1 ProteinBRCA2 ProteinCase-Control StudiesCell DifferentiationCell ProliferationDNA DamageDNA RepairEpigenomicsFusion Proteins, bcr-ablGene Expression ProfilingHumansLeukemia, Lymphocytic, Chronic, B-CellMiceMice, SCIDModels, MolecularMutationNeoplasm Recurrence, LocalNeoplastic Stem CellsOligonucleotide Array Sequence AnalysisPeptide FragmentsRad51 RecombinaseRad52 DNA Repair and Recombination ProteinReal-Time Polymerase Chain ReactionRecombination, GeneticReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTumor Cells, CulturedXenograft Model Antitumor Assays